I could be argued that it would make most sense, if NNZ-2591 has successful results in all 4 current indications, for a well-resourced pharma to run concurrent Phase 3 trials. But from a risk-managing perspective, that might not be an attractive option for them.
Also, outside of those 4 indications, where does Acadia stand with NNZ-2591 in Rett and Fragile-X? Phase 2 or 3 trials are yet to be held and so are quite some years away from any FDA approval. Why would Acadia bother if, say, NNZ-2591 in PMS was approved in a few years’ time, setting off the ticking of the IRA clock on Acadia's in-licensed NNZ-2591 Rett and Fragile-X assets?
What does make sense to me is for Neuren to continue to proceed full steam ahead on Phase 3 in PMS as that just continues to add value. I think the big decision-making point wouldn’t come until the time of any NDA submission and, in the meantime, the IRA law might have been amended and/or Neuren might have already been acquired and it’s someone else’s decision to make!
- Forums
- ASX - By Stock
- NEU
- Ann: Trading Halt
Ann: Trading Halt, page-96
-
- There are more pages in this discussion • 136 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$13.33 |
Change
-0.480(3.48%) |
Mkt cap ! $1.703B |
Open | High | Low | Value | Volume |
$13.82 | $13.91 | $13.32 | $4.989M | 369.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $13.32 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.41 | 1680 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 13.320 |
4 | 8758 | 13.300 |
1 | 2114 | 13.290 |
2 | 1885 | 13.280 |
1 | 2114 | 13.270 |
Price($) | Vol. | No. |
---|---|---|
13.410 | 1680 | 2 |
13.440 | 2114 | 1 |
13.450 | 215 | 1 |
13.470 | 2114 | 1 |
13.490 | 2114 | 1 |
Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |